Single Use Bioreactors Market: Growth, Trends, Applications, and Future Outlook

The Single Use Bioreactors Market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly adopt flexible, scalable, and cost-efficient bioprocessing technologies. Single-use bioreactors (SUBs), also known as disposable bioreactors, use specially engineered disposable vessels or bags instead of conventional stainless-steel tanks for cultivating cells and microorganisms.

The technology has become increasingly important in the development and manufacturing of biologics, vaccines, monoclonal antibodies, cell and gene therapies, and other advanced biological products. According to recent industry estimates, the global single-use bioreactor market was valued at approximately USD 5.46 billion in 2025 and is projected to reach USD 23.17 billion by 2034, representing a CAGR of about 17.43% during the forecast period.

Another market assessment estimates that the industry could reach approximately USD 18.65 billion by 2033, reflecting the strong growth expected from single-use technologies across biopharmaceutical manufacturing.

What Are Single Use Bioreactors?

A bioreactor is a controlled vessel used to grow biological organisms or cells under carefully regulated conditions. Traditional bioreactors are generally constructed from stainless steel and require extensive cleaning, sterilization, validation, and maintenance between production batches.

Single-use bioreactors replace the reusable vessel or culture container with a disposable sterile bag or liner. These systems can incorporate sensors, mixing mechanisms, gas-transfer systems, temperature controls, and other components required for controlled cell culture.

The technology is particularly valuable in biopharmaceutical manufacturing because production requirements can change rapidly. Manufacturers may need to produce different products, conduct clinical trials, or scale production without investing heavily in permanent infrastructure.

Major Growth Drivers of the Single Use Bioreactors Market

Rising Demand for Biologics

The increasing development and commercialization of biologic medicines is one of the strongest factors driving the single-use bioreactors market.

Biologics include monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and other complex biological products. Their manufacturing often requires sophisticated cell-culture systems capable of maintaining precise environmental conditions.

Single-use bioreactors provide manufacturers with flexible platforms for cell cultivation and process development. As pharmaceutical companies expand their biologics pipelines, demand for efficient upstream manufacturing technologies is expected to increase.

The growing demand for biologics and biosimilars has already been identified as a major driver of single-use bioreactor adoption.

Growing Adoption of Flexible Manufacturing

Pharmaceutical manufacturing is moving toward more flexible production models. Instead of relying exclusively on large permanent facilities, companies increasingly require manufacturing systems that can be rapidly configured for different products and production volumes.

Single-use bioreactors support this model by reducing the need for extensive cleaning and sterilization infrastructure. Once a production campaign is completed, the disposable vessel can be replaced with a new sterile assembly.

This flexibility is particularly valuable for contract development and manufacturing organizations (CDMOs), which may manufacture products for multiple pharmaceutical companies.

Reduced Risk of Cross-Contamination

Cross-contamination is an important concern in pharmaceutical manufacturing. Traditional stainless-steel equipment must undergo rigorous cleaning and sterilization procedures between batches.

Single-use systems reduce the dependence on these procedures because the product-contact components are discarded after use. With appropriate qualification and validation, single-use technologies can help reduce contamination risks and simplify changeover processes.

This benefit makes SUBs particularly attractive for facilities producing multiple biologic products or operating smaller production campaigns.

Lower Infrastructure Requirements

Traditional stainless-steel bioreactors require substantial supporting infrastructure, including cleaning-in-place systems, sterilization systems, piping, water systems, and associated utilities.

Single-use systems can reduce the need for some of this infrastructure. This can be especially valuable for new facilities, pilot-scale manufacturing sites, and companies seeking to expand production capacity without building highly complex facilities.

Lower infrastructure requirements can also support faster facility deployment and greater manufacturing flexibility.

Applications of Single Use Bioreactors

Single-use bioreactors are used across research, process development, clinical manufacturing, and commercial biopharmaceutical production.

Monoclonal Antibody Production

Monoclonal antibodies are one of the most important applications for single-use bioreactors. These therapies are used to treat cancer, autoimmune disorders, inflammatory diseases, and other medical conditions.

Mammalian cell cultures are commonly used to produce complex biologic molecules, making controlled bioreactor systems essential for maintaining cell growth and product quality.

The mammalian cell segment represents a major part of the single-use bioreactor industry, reflecting the technology's importance in biologics manufacturing.

Vaccine Manufacturing

Single-use bioreactors are increasingly used in vaccine development and production. Their scalability and flexibility can support rapid manufacturing changes when vaccine demand increases.

The COVID-19 pandemic highlighted the importance of flexible biomanufacturing capacity and resilient supply chains. As governments and pharmaceutical companies strengthen preparedness for future outbreaks, demand for adaptable bioprocessing technologies may increase.

Cell and Gene Therapy

Cell and gene therapies require highly controlled manufacturing environments. Single-use bioreactors can support cell expansion and process development for certain advanced therapy applications.

The growing pipeline of personalized and advanced therapies is expected to create additional opportunities for single-use technologies, particularly in smaller-scale and specialized manufacturing environments.

Research and Process Development

Single-use bioreactors are also widely used in research laboratories and process development. Small-scale systems allow researchers to evaluate cell cultures and optimize process parameters before moving toward larger production volumes.

This makes them valuable during preclinical research, formulation development, process optimization, and clinical-stage manufacturing.

Stirred-Tank Bioreactors and Other Technologies

The single-use bioreactor market includes different technologies, including stirred-tank systems, wave-mixed bioreactors, and other specialized designs.

Stirred-tank single-use bioreactors represent a major market segment because they can support a broad range of mammalian-cell and microbial applications. These systems provide controlled mixing, gas transfer, temperature management, and other process parameters.

Wave-mixed bioreactors use rocking motion to provide mixing and gas transfer and are particularly useful for certain laboratory, development, and smaller-scale applications.

The choice of bioreactor technology depends on factors such as cell type, product requirements, production scale, process design, and manufacturing objectives.

Role of CROs and CDMOs

Contract research organizations and contract development and manufacturing organizations are becoming increasingly important end users of single-use bioreactors.

Pharmaceutical companies frequently outsource research, development, clinical manufacturing, and commercial production to specialized organizations. This creates a strong requirement for flexible manufacturing equipment capable of supporting different products and batch sizes.

Recent market research indicates that CROs and CMOs/CDMOs represent a significant share of the single-use bioreactor market and are expected to remain among the fastest-growing end-user groups.

Single-use technology allows these organizations to change production campaigns more efficiently, reduce downtime, and support multiple clients using flexible manufacturing platforms.

Large-Scale Production Creates New Opportunities

Although single-use bioreactors were initially associated primarily with laboratory and small-scale applications, their use is increasingly expanding into larger production environments.

The development of large-volume single-use bioreactors is enabling manufacturers to produce greater quantities of biological products while maintaining the advantages of disposable technology.

Market research indicates that large-scale production is expected to record strong growth as demand for commercial biologics increases and manufacturers expand production capacity.

This transition represents an important development because it expands the addressable market for single-use systems beyond research and clinical manufacturing.

Regional Outlook

North America

North America is one of the leading regions in the global single-use bioreactor market. The region benefits from a large pharmaceutical and biotechnology industry, substantial investment in biologics, advanced research infrastructure, and strong adoption of innovative manufacturing technologies.

According to Grand View Research, North America accounted for approximately 34.24% of the global market revenue in 2024.

The United States is particularly important because of its large biopharmaceutical manufacturing base and extensive clinical research activity.

Europe

Europe is another important market for single-use bioreactors. Pharmaceutical manufacturers in countries such as Germany, Switzerland, the United Kingdom, France, and Denmark are investing in advanced bioprocessing technologies.

The region's emphasis on manufacturing efficiency, quality standards, sustainability, and pharmaceutical innovation supports the adoption of single-use systems.

Asia Pacific

Asia Pacific is expected to represent one of the fastest-growing regional markets. Countries including China, India, Japan, and South Korea are expanding their pharmaceutical and biotechnology manufacturing capabilities.

Increasing investment in biologics, biosimilars, vaccines, contract manufacturing, and biotechnology research is creating substantial opportunities for single-use bioreactor suppliers.

India, in particular, is strengthening its domestic bioprocessing ecosystem. Recent industry reporting indicates increasing adoption of locally manufactured single-use technologies and continued investment in biopharmaceutical infrastructure.

Sustainability and Environmental Considerations

Sustainability is becoming an increasingly important consideration in biopharmaceutical manufacturing.

At first glance, disposable equipment may appear less environmentally friendly because it generates solid waste after each production cycle. However, single-use systems can reduce the water, energy, cleaning chemicals, and infrastructure requirements associated with reusable stainless-steel equipment.

Industry analysis has highlighted potential reductions in energy and water consumption when single-use systems replace conventional cleaning and sterilization processes.

Manufacturers are therefore working on improved materials, recycling strategies, waste-to-energy approaches, and more sustainable disposable components.

The future development of the industry is likely to focus not only on manufacturing efficiency but also on reducing the environmental footprint of disposable bioprocessing equipment.

Challenges in the Single Use Bioreactors Market

Despite their advantages, single-use bioreactors face several challenges.

One major concern is the disposal of used plastic components. Pharmaceutical manufacturers must manage waste responsibly and comply with environmental and facility requirements.

Another challenge involves the supply chain for single-use bags, films, sensors, connectors, and other specialized components. Supply disruptions can affect manufacturing operations, particularly when facilities rely on specialized suppliers.

Material compatibility and extractables and leachables are also important considerations. Manufacturers must carefully evaluate materials that come into contact with biological products to ensure product quality and process safety.

Additionally, the transition from stainless-steel equipment to single-use systems may require workforce training, process redesign, and investment in new equipment and validation procedures.

Future Trends in the Single Use Bioreactors Market

The future of the market is expected to be shaped by several technological developments.

Automation and Digital Biomanufacturing

Single-use bioreactors are increasingly being integrated with automation systems, sensors, data analytics, and process monitoring platforms.

Digital technologies can provide real-time information about temperature, pH, dissolved oxygen, agitation, pressure, and other process variables. Advanced analytics and machine learning can potentially help manufacturers identify process deviations and optimize production conditions.

Continuous Bioprocessing

The shift toward continuous bioprocessing is another important trend. Continuous manufacturing can support more efficient production and potentially reduce facility footprints.

Single-use systems are well suited to flexible process configurations, making them attractive components in emerging continuous biomanufacturing platforms.

Advanced Cell and Gene Therapies

As cell and gene therapies progress from research to commercial manufacturing, demand for flexible and scalable cell-culture technologies is expected to increase.

Single-use bioreactors can support various stages of advanced therapy development, creating new opportunities for specialized systems and accessories.

Expansion of Large-Volume Systems

The development of larger single-use bioreactors is expanding the technology's role in commercial manufacturing. As manufacturers become more comfortable with single-use technology at larger scales, adoption could increase across major biopharmaceutical production facilities.

Competitive Landscape

The competitive landscape includes major companies operating across bioprocessing equipment, life-science technologies, and pharmaceutical manufacturing solutions. Important industry participants include Sartorius, Thermo Fisher Scientific, Merck, Danaher, Eppendorf, and other specialized bioprocessing technology providers.

Competition is increasingly focused on improving scalability, sensor integration, automation, material performance, process monitoring, and system reliability.

Companies are also developing application-specific solutions for cell therapy, vaccine manufacturing, monoclonal antibody production, and commercial-scale biologics manufacturing.

Conclusion

The Single Use Bioreactors Market is becoming a critical part of modern biopharmaceutical manufacturing. Rising demand for biologics, vaccines, monoclonal antibodies, biosimilars, and advanced therapies is encouraging pharmaceutical and biotechnology companies to adopt flexible and scalable bioprocessing technologies.

The advantages of single-use bioreactors—including reduced cleaning requirements, lower infrastructure needs, faster changeovers, flexibility, and reduced cross-contamination risks—make them attractive alternatives to conventional stainless-steel systems.

North America currently represents a major market, while Asia Pacific is positioned for strong future growth as pharmaceutical and biotechnology manufacturing expands. At the same time, automation, digital biomanufacturing, continuous processing, large-scale disposable systems, and advanced therapies are expected to create new growth opportunities.

As biopharmaceutical manufacturers continue to prioritize speed, flexibility, scalability, and cost efficiency, single-use bioreactors are likely to remain an important technology in the evolution of modern healthcare and biotechnology manufacturing.